Most Recent
A unit of Suncorp Group has reached an in-principle settlement in a class action over alleged conflicted remuneration on the first day of an expected 25-day trial.
The Commonwealth Bank of Australia will bring its second bid to dismiss a case brought by customers who claim they were the victims of "cuckoo-smurfing" and had funds seized as proceeds of crime because the bank breached its anti-money laundering obligations.
The applicants in a class action against The Cosmetic Institute and twelve doctors over allegedly "incompetent" breast augmentation surgery have won court approval to expand their case to allege misleading and deceptive conduct and breaches of the consumer guarantees in the Australian Consumer Law.
Actor Craig McLachlan has dropped his defamation suit against the ABC, Fairfax and actress Christie Whelan Browne mid-trial just as the defence was due to start its case.
The High Court has refused Sydney retail personality Con Constantine’s bid to challenge a $4.25 million judgment in his favour over the $81.8 million Parklea Markets sale in 2016.
Clive Palmer-owned Queensland Nickel Sales has lost its bid to bring a breach of trust lawsuit against the liquidators of Queensland Nickel to recoup $102 million transferred after the billionaire suffered a courtroom defeat last year.
A long-running class action over the Opal Tower disaster has settled, along with two related cases over the defective building, as a five-week trial was set to begin.
Two insurers have won an appeal that blocks group members in a class action against sandalwood producer Quintis from receiving a further $11.25 million after a settlement was reached almost two years ago.
Shine Lawyers has beaten out class action rival Piper Alderman in a battle to lead a class action worth up to $463 million against collapsed wealth managers Dixon Advisory, with a judge finding the firm's no win, no fee model was likely to result in a greater return to group members.
Regenerative medicine company Mesoblast is facing another class action over claims it misled shareholders about the potential application of a developmental stem cell product to treat terminally ill children.